Outpatient 60‐hour day‐and‐night glucose control with dual‐hormone artificial pancreas, single‐hormone artificial pancreas, or sensor‐augmented pump therapy in adults with type 1 diabetes: An open‐label, randomised, crossover, controlled trial
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: To assess whether the dual‐hormone (insulin and glucagon) artificial pancreas reduces hypoglycaemia compared to the single‐hormone (insulin alone) artificial pancreas in outpatient settings during the day and night. Material and methods: In a randomized, three‐way, crossover trial we compared the dual‐hormone artificial pancreas, the single‐hormone artificial pancreas and sensor‐augmented pump therapy (control) in 23 adults with type 1 diabetes. Each intervention was applied from 8 AM Day 1 to 8 PM Day 3 (60 hours) in outpatient free‐living conditions. The primary outcome was time spent with sensor glucose levels below 4.0 mmol/ L . A P value of less than .017 was regarded as significant. Results: The median difference between the dual‐hormone system and the single‐hormone system was −2.3% ( P = .072) for time spent below 4.0 mmol/ L , −1.3% ( P = .017) for time below 3.5 mmol/ L , and −0.7% ( P = .031) for time below 3.3 mmol/ L . Both systems reduced ( P < .017) hypoglycaemia below 4.0, 3.5 and 3.3 mmol/ L compared to control therapy, but reductions were larger with the dual‐hormone system than with the single‐hormone system (medians −4.0% vs −3.4% for 4.0 mmol/ L ; −2.7% vs −2.2% for 3.5 mmol/ L ; and −2.2% vs −1.2% for 3.3 mmol/ L ). There were 34 hypoglycaemic events (<3.0 mmol/ L for 20 minutes) with control therapy, 14 with the single‐hormone system and 6 with the dual‐hormone system. These differences in hypoglycaemia were observed while mean glucose level was low and comparable in all interventions ( P = NS ). Conclusions: The dual‐hormone artificial pancreas had the lowest risk of hypoglycaemia, but the differences were not statistically significant. Larger studies are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“Hypoglycaemia remains the major barrier to achieving glycaemic targets.(2) Non-severe hypoglycaemia can trigger adrenergic and neurologic symptoms, and occurs 2 to 3 times per patient per week.”
BackgroundHome Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Feltbower, R. G., Bodansky, H. J., Patterson, C. C., Parslow, R. C., Stephenson, C. R., Reynolds, C., & McKinney, P. A. (2008) · Diabetes Care · doi:10.2337/dc07-2029 · Cited by 183 · cited 1×
“Moreover, recurrent severe hypoglycaemia can cause morbidity and mortality, and up to 10% of deaths in type 1 diabetes may be attributed to severe hypoglycaemia.(5) Because of the fear of hypoglycaemia, many patients take too little insulin and experience sustained elevated glucose levels.”
BackgroundHaidar, A., Legault, L., Dallaire, M., Alkhateeb, A., Coriati, A., Messier, V., Cheng, P., Millette, M., Boulet, B., & Rabasa-Lhoret, R. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.121265 · Cited by 167
Self-citationPathak, R. D., Schroeder, E. B., Seaquist, E. R., Zeng, C., Lafata, J. E., Thomas, A., Desai, J., Waitzfelder, B., Nichols, G. A., Lawrence, J. M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-0858 · Cited by 140
Multinational Home Use of Closed-Loop Control Is Safe and Effective
Anderson, S. M., Raghinaru, D., Pinsker, J. E., Boscari, F., Renard, E., Buckingham, B. A., Nimri, R., Doyle, F. J., Brown, S. A., Keith-Hynes, P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2468 · Cited by 120
Renard, E., Farret, A., Kropff, J., Bruttomesso, D., Messori, M., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0008 · Cited by 104
Cited by
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Bekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
New closed-loop insulin systems
Boughton, C. K., & Hovorka, R. (2021) · Diabetologia · doi:10.1007/s00125-021-05391-w · Cited by 270
Benhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Fang, Z., Liu, M., Tao, J., Li, C., Zou, F., & Zhang, W. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01674-6 · Cited by 38
Metadata
- Authors
- Haidar, A., Messier, V., Legault, L., Ladouceur, M., & Rabasa‐Lhoret, R.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-08
- Volume
- 19
- Issue
- 5
- Pages
- 713-720
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2577069570
- Cited by
- 81
- References
- 11
- FWCI
- 8.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.